Eyevensys said today that it took a Series A round to $10 million (€9 million) after an extension led by Pontifax Venture Capital. The Paris-based biotech said it plans to use the funds to secure clinical development of EYS606, its lead candidate for the treatment of non-infectious uveitis. Its EyeCET technology is the 1st non-viral product that […]
